Developer docs
API playgroundTry for free, no card

Search company profiles

Vimian Group

Full company profile

uuid0006y46

Namestring
Vimian Group
Legal namestring
Vimian Group AB (publ)
Websiteurl
vimian.com
Company typeenum
Public
Founded yearint
2021
Descriptiontext

Vimian Group AB is a Stockholm-based global animal health company operating through four business segments: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics. Founded in 2021 and listed on Nasdaq Stockholm (moved to the Main Market in 2025), the company serves veterinary professionals and animal health clinics across 80 markets with approximately 1,300 employees. The portfolio is delivered through five wholly-owned operating subsidiaries — Nextmune (allergy diagnostics and treatment), Movora (surgical and orthopedic products), Indical Bioscience (diagnostics and bioscience), VetFamily (veterinary practice services), and Heiland (veterinary products) — plus recently acquired brands I-Vet, Biofleet, Vet-Allergy, Kahu Vet Group, and AllAccem. In FY2025, Vimian reported EUR 425.0 million in revenue and EUR 105.3 million in adjusted EBITA (13% and 11% growth, respectively), launched 94 new products, and educated 65,000 veterinary professionals.

The company runs an acquisition-driven platform model: it integrates specialty animal health businesses under a single corporate umbrella while preserving acquired brand identities, and grows them through shared distribution, R&D, and professional training. Its go-to-market is B2B, distributing products and services directly to veterinary clinics and animal health professionals. Revenue mechanics blend one-time product sales (MedTech surgical products and equipment, Specialty Pharma products) with recurring subscription revenue from the Veterinary Services platform (serving 10,900 member clinics) and reference laboratory diagnostic services. The Q4 2025 organic revenue growth of 6% and EUR 17.5 million revenue contribution from five new businesses added during 2025 illustrate the balance between organic and inorganic growth.

Vimian finances its growth through capital markets: a 2024 rights issue and a EUR 150 million senior unsecured bond issuance in May 2025 (within a EUR 250 million framework). Recent corporate actions include the appointment of Alireza Tajbakhsh as CEO in November 2025, the March 2026 appointment of Lotta Lundaas as Head of Medtech, and the spring 2026 departure of long-tenured Specialty Pharma head Magnus Kjellberg. The company also received EUR 28.7 million in full payment from a U.S. indemnification dispute and achieved an AAA sustainability rating in May 2026.

Short descriptiontext

Vimian Group AB is a Stockholm-based global animal health company operating four segments — Specialty Pharma, MedTech, Veterinary Services, and Diagnostics — serving veterinary clinics and professionals across 80 markets through wholly-owned subsidiaries and an integrated B2B platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersStockholm, Sweden
HQ citystring
Stockholm
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
animal health products, veterinary pharmaceuticals, veterinary medical devices, animal diagnostics services, veterinary practice services
Industry2 codes
PRIMARYHLAMAIAG
Veterinary Distributor Value-Added Services (3PL, Cold Chain, Returns)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Distribution & Retail (Wholesalers, Pharmacies)
SECONDARYHLAMAIAH
Specialty Veterinary Therapeutics Distribution (Oncology, Dermatology, Endocrinology)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Distribution & Retail (Wholesalers, Pharmacies)
NAICS code3 codes
  • Veterinary Services54194
  • Veterinary Services541940
  • Support Activities for Animal Production11521
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Surgical & Medical Instruments & Apparatus3841
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Animal Health Products and Services
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Product Sales - Specialty Pharma
TypeSubscription Recurring
Description

Revenue from pharmaceutical products for animal health sold to veterinary professionals and clinics

tradingview.com
2Product Sales - MedTech
TypeOne Time License
Description

Revenue from veterinary surgical products and medical equipment sold to veterinary clinics

tradingview.com
3Veterinary Services
TypeSubscription Recurring
Description

Subscription-style platform services to member veterinary clinics with recurring revenue

tradingview.com
4Diagnostic Services
TypeSubscription Recurring
Description

Reference laboratory and diagnostic testing services for companion animals

tradingview.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Nextmune
Description

Animal health - allergy diagnostics and treatment

vimian.com
+4 more records
Core offering1 text field

Vimian is a global animal health company that develops, manufactures, and distributes veterinary pharmaceuticals, medical technology products, diagnostic services, and practice-support services through four segments — Specialty Pharma, MedTech, Veterinary Services, and Diagnostics — serving veterinary professionals and clinics across 80 markets. The company combines proprietary products with a 10,900-member clinic services platform and extensive professional training programs to grow acquired specialty businesses globally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • EUR 425 million in revenues (2025), a 13% increase from prior year
+4 more records
Product overview1 text field

Vimian Group is a global animal health company operating as a platform of four core segments: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics. The company has grown through acquisitions of specialized brands including Nextmune (allergy products), Movora (surgical/orthopedic products), VetFamily (practice management services), Indical (bioscience diagnostics), I-Vet and Biofleet (Italian diagnostics), Vet-Allergy (Danish allergy diagnostics), and Kahu Vet Group (surgical products in ANZ). The Veterinary Services platform serves approximately 10,900 member clinics. The company generated EUR 425 million in revenues in 2025 with operations across 80 markets.

Product and service11 records
1Specialty Pharma
CategorySpecialty Pharmaceutical Products
Description

Pharmaceutical products for animal health conditions, including specialty medications for companion and production animals, sold to veterinary professionals and clinics.

2MedTech
CategoryVeterinary Medical Devices
Description

Medical technology products for veterinary use, including surgical instruments, orthopedic implants, and devices for veterinary procedures, sold to veterinary clinics.

3Veterinary Services
CategoryVeterinary Practice Services
Description

Subscription-style practice management services, professional networks, and support platforms for veterinary clinics, currently serving approximately 10,900 member clinics.

4Diagnostics
CategoryAnimal Health Diagnostics
Description

Companion animal diagnostic services including reference laboratory testing and diagnostic solutions sold to veterinary clinics and professionals.

5Nextmune
CategoryAllergy Pharmaceuticals and Diagnostics
Description

Animal health allergy diagnostics and treatment products and services within Vimian's Specialty Pharma portfolio.

6Movora
CategoryVeterinary Surgical and Orthopedic Devices
Description

Veterinary surgical products and orthopedic solutions provider within Vimian's MedTech segment.

7VetFamily
CategoryVeterinary Practice Services
Description

Veterinary services platform providing practice management support, professional education, and business services to veterinary clinics (10,900 member clinics).

8Indical Bioscience
CategoryAnimal Health Diagnostics
Description

Bioscience diagnostics products and services for animal health, including molecular and reference laboratory diagnostic kits.

9I-Vet (Italian Diagnostics)
CategoryAnimal Health Diagnostics
Description

Italian companion animal diagnostic services provider, with reference laboratory and diagnostic services reaching approximately 5,000 veterinary clinics across Italy.

10Vet-Allergy
CategoryAllergy Diagnostics and Treatment
Description

Veterinary allergy diagnostics and treatment solutions provider in Denmark, serving over 300 veterinary clinics.

11Kahu Vet Group
CategoryVeterinary Surgical Products Distribution
Description

Veterinary surgical products supplier operating in New Zealand and Australia, with reported 2021 revenues of approximately EUR 8.5 million.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Franzini Family
Strategic tierMinorTypeOthersAnnounced on2026-03-27
Description

The Franzini family sold I-Vet srl and Biofleet srl to Vimian Group. I-Vet was founded in 2012 and generates approximately EUR 5.6 million in annual revenue with 75 employees serving around 5,000 veterinary clinics across Italy. This was Vimian's fifth strategic transaction of the year 2026.

inforcapital.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-02-12
Description

I-Vet is a leading provider of companion animal diagnostics in Italy. Vimian signed agreement to acquire I-Vet in December 2025, with acquisition completed in March 2026. I-Vet serves 5,000 veterinary clinics and offers reference laboratory and diagnostic services with annual revenues of around EUR 5.6 million.

3Vet-Allergy
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-02-07
Description

Vet-Allergy is a veterinary allergy company in Denmark acquired by Vimian to enhance its position in veterinary allergy diagnostics and treatment in Scandinavia. The company serves over 300 veterinary clinics and is the leading provider of veterinary allergy solutions in Denmark.

finance.yahoo.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-02-03
Description

Kahu Vet Group is a veterinary surgical product supplier in New Zealand and Australia acquired by Vimian as part of its geographic expansion strategy. The company had revenues of approximately EUR 8.5 million in 2021. Purchase price was EUR 12.1 million upfront with potential earn-outs of up to EUR 10.4 million based on performance.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Zoetis is the world's largest pure-play animal health company, spanning pharma, diagnostics, and devices across companion and livestock. It is the dominant incumbent against which Vimian competes in Specialty Pharma and Diagnostics, with materially larger R&D and global reach.

TypeBroad incumbent
Description

IDEXX is the leading companion animal diagnostics company globally, with reference lab services (IDEXX Reference Laboratories) and in-clinic analyzers. It is the most direct large-scale competitor to Vimian's Diagnostics segment and a benchmark for recurring vet-channel economics.

TypeBroad incumbent
Description

Elanco is a diversified animal health company with pharma and pet health portfolios (including the acquired Bayer Animal Health). It overlaps with Vimian's Specialty Pharma and MedTech segments and competes in similar veterinary channels.

TypeDirect peer
Description

Virbac is an independent animal health company specializing in veterinary pharmaceuticals, particularly specialty/specialty categories like dermatology, parasiticides, and aquaculture. It is closely comparable to Vimian's Specialty Pharma and allergy businesses (Nextmune).

TypeDirect peer
Description

Vetoquinol is a French independent animal health company focused on specialty pharma (orthopedics, dermatology, cardiology). Like Vimian, it pursues a specialty, non-commoditized positioning in veterinary pharma with mid-sized global scale.

TypeDirect peer
Description

Dechra was a UK-listed specialty veterinary pharma company acquired by Elanco in 2024; it served as a directly comparable specialty-pharma-and-services platform prior to acquisition and represents the archetype Vimian is emulating in its roll-up strategy.

TypeDirect peer
Description

Phibro is a US-listed animal health and nutrition company with specialty pharma (nutritional health, vaccines) and a similarly mid-cap scale. It overlaps with Vimian's Specialty Pharma positioning and B2B distribution to veterinarians.

8Henry Schein Animal Health (Covetrus heritage)
TypeBroad incumbent
Description

Henry Schein's animal health business (which absorbed Covetrus) is one of the largest distributors of veterinary products in North America. It is comparable to Vimian's B2B distribution model across MedTech and pharma products.

TypeBroad incumbent
Description

Mars Petcare owns Antech Diagnostics (reference labs) and Banfield/BluePearl veterinary hospital chains. It is comparable to Vimian's Diagnostics and Veterinary Services segments at much larger scale, with vertically integrated veterinary care delivery.

TypeEmerging player
Description

Pharmgate is a privately held specialty animal health company focused on parasiticides and therapeutic solutions for livestock and companion animals. It is comparable as a smaller, specialty-focused animal health platform similar to Vimian's Specialty Pharma positioning.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries9 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vimian Group

Animal Health Products and Servicesvimian.com

Vimian Group AB is a Stockholm-based global animal health company operating four segments — Specialty Pharma, MedTech, Veterinary Services, and Diagnostics — serving veterinary clinics and professionals across 80 markets through wholly-owned subsidiaries and an integrated B2B platform.

What Vimian Group does

Vimian Group AB is a Stockholm-based global animal health company operating through four business segments: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics. Founded in 2021 and listed on Nasdaq Stockholm (moved to the Main Market in 2025), the company serves veterinary professionals and animal health clinics across 80 markets with approximately 1,300 employees. The portfolio is delivered through five wholly-owned operating subsidiaries — Nextmune (allergy diagnostics and treatment), Movora (surgical and orthopedic products), Indical Bioscience (diagnostics and bioscience), VetFamily (veterinary practice services), and Heiland (veterinary products) — plus recently acquired brands I-Vet, Biofleet, Vet-Allergy, Kahu Vet Group, and AllAccem. In FY2025, Vimian reported EUR 425.0 million in revenue and EUR 105.3 million in adjusted EBITA (13% and 11% growth, respectively), launched 94 new products, and educated 65,000 veterinary professionals.

The company runs an acquisition-driven platform model: it integrates specialty animal health businesses under a single corporate umbrella while preserving acquired brand identities, and grows them through shared distribution, R&D, and professional training. Its go-to-market is B2B, distributing products and services directly to veterinary clinics and animal health professionals. Revenue mechanics blend one-time product sales (MedTech surgical products and equipment, Specialty Pharma products) with recurring subscription revenue from the Veterinary Services platform (serving 10,900 member clinics) and reference laboratory diagnostic services. The Q4 2025 organic revenue growth of 6% and EUR 17.5 million revenue contribution from five new businesses added during 2025 illustrate the balance between organic and inorganic growth.

Vimian finances its growth through capital markets: a 2024 rights issue and a EUR 150 million senior unsecured bond issuance in May 2025 (within a EUR 250 million framework). Recent corporate actions include the appointment of Alireza Tajbakhsh as CEO in November 2025, the March 2026 appointment of Lotta Lundaas as Head of Medtech, and the spring 2026 departure of long-tenured Specialty Pharma head Magnus Kjellberg. The company also received EUR 28.7 million in full payment from a U.S. indemnification dispute and achieved an AAA sustainability rating in May 2026.

Vimian Group firmographics

Firmographics
Name
Vimian Group
Legal name
Vimian Group AB (publ)
Website
https://vimian.com
Company type
Public
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Vimian Group AB is a Stockholm-based global animal health company operating four segments — Specialty Pharma, MedTech, Veterinary Services, and Diagnostics — serving veterinary clinics and professionals across 80 markets through wholly-owned subsidiaries and an integrated B2B platform.
Ownership category
akta.pro rank

Vimian Group industry classification

Industry
Product category
Animal Health Products and Services
NAICS
Veterinary Services (54194), Veterinary Services (541940), Support Activities for Animal Production (11521)
SIC
Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro industry
PRIMARYHLAMAIAG
Veterinary Distributor Value-Added Services (3PL, Cold Chain, Returns)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Distribution & Retail (Wholesalers, Pharmacies)
SECONDARYHLAMAIAH
Specialty Veterinary Therapeutics Distribution (Oncology, Dermatology, Endocrinology)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Distribution & Retail (Wholesalers, Pharmacies)

Keywords

  • Animal health products
  • Veterinary pharmaceuticals
  • Veterinary medical devices
  • Animal diagnostics services
  • Veterinary practice services

Where Vimian Group is headquartered

Location

Headquarters

HQ city
Stockholm
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Vimian Group business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Product Sales - Specialty Pharma: Revenue from pharmaceutical products for animal health sold to veterinary professionals and clinics
  2. Product Sales - MedTech: Revenue from veterinary surgical products and medical equipment sold to veterinary clinics
  3. Veterinary Services: Subscription-style platform services to member veterinary clinics with recurring revenue
  4. Diagnostic Services: Reference laboratory and diagnostic testing services for companion animals

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Vimian Group product offering

Product offering

Core offering

Vimian is a global animal health company that develops, manufactures, and distributes veterinary pharmaceuticals, medical technology products, diagnostic services, and practice-support services through four segments — Specialty Pharma, MedTech, Veterinary Services, and Diagnostics — serving veterinary professionals and clinics across 80 markets. The company combines proprietary products with a 10,900-member clinic services platform and extensive professional training programs to grow acquired specialty businesses globally.

Product overview

Vimian Group is a global animal health company operating as a platform of four core segments: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics. The company has grown through acquisitions of specialized brands including Nextmune (allergy products), Movora (surgical/orthopedic products), VetFamily (practice management services), Indical (bioscience diagnostics), I-Vet and Biofleet (Italian diagnostics), Vet-Allergy (Danish allergy diagnostics), and Kahu Vet Group (surgical products in ANZ). The Veterinary Services platform serves approximately 10,900 member clinics. The company generated EUR 425 million in revenues in 2025 with operations across 80 markets.

Differentiator

Problem solved

Functional benefit

Brands

  • Nextmune: Animal health - allergy diagnostics and treatment
  • Movora
  • Indical Bioscience
  • VetFamily
  • Heiland

Products and services

  • Specialty Pharma Pharmaceutical products for animal health conditions, including specialty medications for companion and production animals, sold to veterinary professionals and clinics.
  • MedTech Medical technology products for veterinary use, including surgical instruments, orthopedic implants, and devices for veterinary procedures, sold to veterinary clinics.
  • Veterinary Services Subscription-style practice management services, professional networks, and support platforms for veterinary clinics, currently serving approximately 10,900 member clinics.
  • Diagnostics Companion animal diagnostic services including reference laboratory testing and diagnostic solutions sold to veterinary clinics and professionals.
  • Nextmune Animal health allergy diagnostics and treatment products and services within Vimian's Specialty Pharma portfolio.
  • Movora Veterinary surgical products and orthopedic solutions provider within Vimian's MedTech segment.
  • VetFamily Veterinary services platform providing practice management support, professional education, and business services to veterinary clinics (10,900 member clinics).
  • Indical Bioscience Bioscience diagnostics products and services for animal health, including molecular and reference laboratory diagnostic kits.
  • I-Vet (Italian Diagnostics) Italian companion animal diagnostic services provider, with reference laboratory and diagnostic services reaching approximately 5,000 veterinary clinics across Italy.
  • Vet-Allergy Veterinary allergy diagnostics and treatment solutions provider in Denmark, serving over 300 veterinary clinics.
  • Kahu Vet Group Veterinary surgical products supplier operating in New Zealand and Australia, with reported 2021 revenues of approximately EUR 8.5 million.

Quantifiable outcome

  • EUR 425 million in revenues (2025), a 13% increase from prior year
  • +4 more outcomes

Companies that use Vimian Group

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles1 record

Vimian Group technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Vimian Group partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor.

  • Franzini FamilyminorOthers · 27 March 2026The Franzini family sold I-Vet srl and Biofleet srl to Vimian Group. I-Vet was founded in 2012 and generates approximately EUR 5.6 million in annual revenue with 75 employees serving around 5,000 veterinary clinics across Italy. This was Vimian's fifth strategic transaction of the year 2026.
  • I-VetminorStrategic or Co-development Partner · 12 February 2026I-Vet is a leading provider of companion animal diagnostics in Italy. Vimian signed agreement to acquire I-Vet in December 2025, with acquisition completed in March 2026. I-Vet serves 5,000 veterinary clinics and offers reference laboratory and diagnostic services with annual revenues of around EUR 5.6 million.
  • Vet-AllergyminorStrategic or Co-development Partner · 7 February 2022Vet-Allergy is a veterinary allergy company in Denmark acquired by Vimian to enhance its position in veterinary allergy diagnostics and treatment in Scandinavia. The company serves over 300 veterinary clinics and is the leading provider of veterinary allergy solutions in Denmark.
  • Kahu Vet GroupminorStrategic or Co-development Partner · 3 February 2022Kahu Vet Group is a veterinary surgical product supplier in New Zealand and Australia acquired by Vimian as part of its geographic expansion strategy. The company had revenues of approximately EUR 8.5 million in 2021. Purchase price was EUR 12.1 million upfront with potential earn-outs of up to EUR 10.4 million based on performance.

Scale indicators15 records

Recent moves7 records

Expansion highlights6 records

Vimian Group competitors and assessment

Company assessment

Broad incumbents

  • Zoetis: Zoetis is the world's largest pure-play animal health company, spanning pharma, diagnostics, and devices across companion and livestock. It is the dominant incumbent against which Vimian competes in Specialty Pharma and Diagnostics, with materially larger R&D and global reach.
  • IDEXX Laboratories: IDEXX is the leading companion animal diagnostics company globally, with reference lab services (IDEXX Reference Laboratories) and in-clinic analyzers. It is the most direct large-scale competitor to Vimian's Diagnostics segment and a benchmark for recurring vet-channel economics.
  • Elanco Animal Health: Elanco is a diversified animal health company with pharma and pet health portfolios (including the acquired Bayer Animal Health). It overlaps with Vimian's Specialty Pharma and MedTech segments and competes in similar veterinary channels.
  • Henry Schein Animal Health (Covetrus heritage): Henry Schein's animal health business (which absorbed Covetrus) is one of the largest distributors of veterinary products in North America. It is comparable to Vimian's B2B distribution model across MedTech and pharma products.
  • Mars Petcare / Antech Diagnostics: Mars Petcare owns Antech Diagnostics (reference labs) and Banfield/BluePearl veterinary hospital chains. It is comparable to Vimian's Diagnostics and Veterinary Services segments at much larger scale, with vertically integrated veterinary care delivery.

Direct peers

  • Virbac: Virbac is an independent animal health company specializing in veterinary pharmaceuticals, particularly specialty/specialty categories like dermatology, parasiticides, and aquaculture. It is closely comparable to Vimian's Specialty Pharma and allergy businesses (Nextmune).
  • Vetoquinol: Vetoquinol is a French independent animal health company focused on specialty pharma (orthopedics, dermatology, cardiology). Like Vimian, it pursues a specialty, non-commoditized positioning in veterinary pharma with mid-sized global scale.
  • Dechra Pharmaceuticals: Dechra was a UK-listed specialty veterinary pharma company acquired by Elanco in 2024; it served as a directly comparable specialty-pharma-and-services platform prior to acquisition and represents the archetype Vimian is emulating in its roll-up strategy.
  • Phibro Animal Health: Phibro is a US-listed animal health and nutrition company with specialty pharma (nutritional health, vaccines) and a similarly mid-cap scale. It overlaps with Vimian's Specialty Pharma positioning and B2B distribution to veterinarians.

Emerging players

  • Pharmgate Animal Health: Pharmgate is a privately held specialty animal health company focused on parasiticides and therapeutic solutions for livestock and companion animals. It is comparable as a smaller, specialty-focused animal health platform similar to Vimian's Specialty Pharma positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Vimian Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vimian Group leadership team

Management profile

Number of profiles

Profiles4 records

Vimian Group subsidiaries and ownership

Company hierarchy

Subsidiaries9 records

Vimian Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vimian Group M&A and investment

M&A and investment

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vimian Group

What does Vimian Group do?

Vimian is a global animal health company that develops, manufactures, and distributes veterinary pharmaceuticals, medical technology products, diagnostic services, and practice-support services through four segments — Specialty Pharma, MedTech, Veterinary Services, and Diagnostics — serving veterinary professionals and clinics across 80 markets. The company combines proprietary products with a 10,900-member clinic services platform and extensive professional training programs to grow acquired specialty businesses globally.

Is Vimian Group a public or private company?

Vimian Group is a public company. It is classified as public and is currently operating.

When was Vimian Group founded?

Vimian Group was founded in 2021. It employs 11 to 50 people.

Where is Vimian Group based?

Vimian Group is headquartered in Stockholm, Sweden, in the Europe region.

How does Vimian Group make money?

Four revenue lines are on record. Product Sales - Specialty Pharma is the primary driver. The others are product Sales - MedTech, veterinary Services and diagnostic Services.

Who are Vimian Group's main competitors?

Broad incumbents on record are Zoetis, IDEXX Laboratories, Elanco Animal Health, Henry Schein Animal Health (Covetrus heritage) and Mars Petcare / Antech Diagnostics. Direct peers are Virbac, Vetoquinol, Dechra Pharmaceuticals and Phibro Animal Health. Pharmgate Animal Health is listed as an emerging player.

Does Vimian Group have an API?

No public API is recorded for Vimian Group.

What industry is Vimian Group in?

Vimian Group's product category is Animal Health Products and Services. Its primary akta.pro industry code is HLAMAIAG, Veterinary Distributor Value-Added Services (3PL, Cold Chain, Returns), with a secondary code of HLAMAIAH, Specialty Veterinary Therapeutics Distribution (Oncology, Dermatology, Endocrinology). Its NAICS code is 54194 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StVimian Group (OM:VIMIAN) Stock Price Faces Q3 Earnings Valuation QuestionVimian Group reported Q3 2026 revenue of €121.4m and net income of €8.9m, up 16% and 37% year-over-year. The stock trades at a P/E of 48.8x, and organic growth of 11% shows underlying engine working, though margin strain and M&A dependence remain concerns.Seeking AlphaVimian Group AB (publ) (VIMGF) Q3 2026 Earnings Call TranscriptVimian Group reported strong Q3 2026 results with double-digit organic growth and 71% operational cash conversion. The company acquired Norfolk Medical Products in the U.S. and hired a new Head of Specialty Pharma. Management also promoted Andrea Tidholm as Head of M&A.Dagens industriÖkad vinst men lägre marginal för VimianVimian reported an adjusted EBITA of 29.2 million euros for Q3 2026, down from 25.5 million euros. The adjusted EBITA margin fell to 24.3 percent from 24.5 percent. The company's CEO Alireza Tajbakhsh commented on the results.MarketScreenerVimian acquires US companyVimian acquired US company Norfolk, which reported sales of about $6.9m (SEK 68m) through August 2026. The deal, financed with existing funds, is expected to close around November 2, with a marginal impact on 2026 earnings per share. The purchase price was not disclosed.TradingViewVimian expands its surgical offering through the acquisition of Norfolk Medical ProductsVimian Group AB agreed to acquire Norfolk Medical Products, a US veterinary soft-tissue surgery implant provider, with revenues of about USD 6.9 million for the year ending August 2026. The deal, financed with available funds, is expected to close around 1 November and integrate into Vimian's MedTech segment, with a marginal impact on 2026 earnings per share.TradingViewVimian Group – Consensus estimates Q3 2026Vimian Group's consensus estimates for Q3 2026 show revenue of 116 MEUR, organic growth of 7.58%, and adjusted EBITA of 28.0 MEUR. Adjusted EBITA margin is 24.19%, EBIT is 20.7 MEUR, and profit is 11.9 MEUR, with EPS of 0.02 EUR. The Q3 report is due Thursday 22 October at 7:45 CEST.Dagens industriVimians storägare miljontankar aktierVimian's major shareholder Fidelio increased its stake by purchasing over 3.3 million shares for a total of 187 million kronor. The acquisition was announced on September 14, 2026, and the company's management is not disclosed.AffarsvarldenVimians huvudägare köper aktier för 187 miljoner kronorFidelio Capital, Vimian's main shareholder, bought 5.48 million shares on September 9-11 for 187.1 million SEK, averaging 34.11 SEK per share. The deal was executed on Nasdaq Stockholm, and Fidelio held 59.61% of capital and 60.21% of votes as of August 27.MarketScreenerHandelsbanken Adds Xvivo and Vimian as Sector Favorites, Drops Danish DuoHandelsbanken added Xvivo and Vimian to its healthcare sector favorites list, removing Genmab and Novo Nordisk. The bank cites Xvivo's upcoming product launches and Vimian's 10% organic sales growth as catalysts. The updated list includes 18 companies, with Xvivo and Vimian now included.Dagens industriVimians största ägare köper aktier för 145 miljonerFidelio Capital, Vimians largest shareholder, increased its stake in the animal health company by buying nearly 4.2 million shares for about 145 million kronor, according to the report. The article is behind a paywall. The accompanying Société Générale piece explains warrants as bank-issued, cash-settled options available through Swedish online brokers.